(S)-p-SCN-Bn-DOTA TFA is a bifunctional chelator (BFC), a macrocyclic DOTA derivative for tumor pretargeting. (S)-p-SCN-Bn-DOTA TFA can be used for the conjugation of peptides and radionuclides, such as as a linker for In-111 labeled radioimmunoconjugates (RICs) for single photon emission tomography (SPECT) and in vitro biodistribution studies [1].
In Vitro, (S)-p-SCN-Bn-DOTA TFA forms serum-stable radioimmunoconjugates with monoclonal antibodies and radioisotopes, retains tumor cell binding activity, enables SPECT visualization of subcutaneous tumor xenografts, and shows preferential tumor uptake in mouse xenograft models[1].
References:
[1]. Xu L, et al. Evaluation of novel DOTA-based linkers for improved targeted radiotherapy delivery to solid tumors[J]. 2024.
In Vitro, (S)-p-SCN-Bn-DOTA TFA forms serum-stable radioimmunoconjugates with monoclonal antibodies and radioisotopes, retains tumor cell binding activity, enables SPECT visualization of subcutaneous tumor xenografts, and shows preferential tumor uptake in mouse xenograft models[1].
References:
[1]. Xu L, et al. Evaluation of novel DOTA-based linkers for improved targeted radiotherapy delivery to solid tumors[J]. 2024.